Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAZOLAMIDE SODIUM vs DICHLORPHENAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Treatment of open-angle glaucoma and secondary glaucoma,Preoperative and perioperative reduction of intraocular pressure in acute angle-closure glaucoma,Treatment of edema due to congestive heart failure when other diuretics are ineffective,Adjunctive treatment of epilepsy (centrencephalic epilepsies, absence seizures),Prophylaxis and treatment of acute mountain sickness
Treatment of increased intraocular pressure in chronic open-angle glaucoma,Secondary glaucoma,Preoperatively in acute angle-closure glaucoma,Off-label: Treatment of familial periodic paralysis,Off-label: Management of altitude sickness
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
25-50 mg orally twice daily.
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Acetazolamide is minimally metabolized in the liver, with the majority of the drug excreted unchanged in the urine. The primary metabolic pathway involves oxidation of the thiadiazole ring, but this is a minor route. The drug is not extensively biotransformed; hepatic metabolism accounts for less than 10% of elimination.
Dichlorphenamide is not extensively metabolized; it is excreted unchanged in urine.
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
70-90% (mainly carbonic anhydrase in RBCs; low affinity for albumin).
90-95% bound to plasma proteins, primarily albumin.
Approximately 0.2-0.3 L/kg; mainly confined to extracellular fluid and highly perfused tissues.
0.2-0.3 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral: ~90-100% (rapidly absorbed; food may delay). Intramuscular: not recommended (acidic p H).
Oral: approximately 80-100% (well absorbed); bioavailability not defined for parenteral routes as not typically given.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: avoid or use with extreme caution.
Cr Cl <50 m L/min: not recommended; Cr Cl 50-80 m L/min: 25 mg once daily; Cr Cl >80 m L/min: no adjustment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to 24-48 hours. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: avoid use.
For edema: 5 mg/kg IV or IM once daily. For glaucoma: 10-15 mg/kg/day IV or IM in divided doses every 6-8 hours.
Not established; safety and efficacy not determined in children.
Initiate at lowest adult dose; monitor renal function and electrolytes; adjust based on creatinine clearance.
Start at 25 mg once daily; monitor renal function and electrolytes.
None
None.
Use with caution in patients with hepatic cirrhosis, as acetazolamide can precipitate hepatic encephalopathy due to increased ammonia levels,May cause metabolic acidosis, which can be severe with prolonged use; monitor serum electrolytes and bicarbonate levels,Can precipitate renal calculi due to decreased urinary citrate excretion; ensure adequate hydration,May cause drowsiness, confusion, or ataxia; caution when operating machinery or driving,Use with caution in patients with respiratory acidosis or chronic obstructive pulmonary disease, as metabolic acidosis may worsen respiratory function,Monitor for signs of hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis,May cause hematologic reactions such as agranulocytosis, aplastic anemia, and thrombocytopenia; monitor blood counts
Metabolic acidosis: Can occur, especially in patients with renal impairment or electrolyte disturbances.,Hypokalemia: Risk may increase due to bicarbonate loss and metabolic acidosis.,Sulfonamide allergy: Cross-sensitivity possible; caution in patients with history of sulfonamide hypersensitivity.,Renal impairment: Use with caution; may accumulate and worsen acidosis.,Hepatic impairment: Caution due to risk of hepatic encephalopathy.,Drug interactions: May increase effects of other carbonic anhydrase inhibitors, furosemide, and decrease effects of lithium.,Pregnancy: Weigh risks vs benefits; not recommended.,Lactation: Excreted in milk; avoid breastfeeding.
Known hypersensitivity to acetazolamide or any sulfonamide-derivative (although cross-reactivity may not occur, caution is advised),Severe hepatic insufficiency or cirrhosis with risk of hepatic encephalopathy,Severe renal impairment (e.g., anuria, glomerular filtration rate <10 m L/min),Metabolic acidosis,Hyponatremia or hypokalemia,Concurrent use with high-dose aspirin (risk of metabolic acidosis and increased salicylate toxicity)
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal impairment (e.g., anuria, severe nephropathy),Severe hepatic disease,Hepatic encephalopathy,Hypokalemia (uncorrected),Metabolic acidosis (uncorrected),Adrenal insufficiency,Hyperchloremic acidosis,Pregnancy (relative contraindication),Lactation (relative contraindication)
No specific food interactions reported. However, high-sodium foods may counteract the diuretic effect. Maintain adequate fluid intake to prevent kidney stones. Avoid large amounts of caffeine as it may increase diuresis and electrolyte loss.
Avoid high-dose aspirin or salicylates; may increase toxicity. Limit alcohol intake to reduce risk of metabolic acidosis. No specific food restrictions but maintain adequate hydration to prevent renal calculi. Avoid cranberry juice if prone to kidney stones.
Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human data limited but suggests potential teratogenicity. Second and third trimesters: may cause fetal metabolic acidosis, electrolyte disturbances, and growth restriction due to carbonic anhydrase inhibition.
Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced fetal weight at doses similar to human therapeutic doses. First trimester exposure may carry a risk of teratogenicity; second and third trimester risks include possible metabolic acidosis and electrolyte disturbances in the fetus.
Acetazolamide is excreted into breast milk in low amounts. M/P ratio is approximately 0.25. Infant exposure is minimal but may cause metabolic acidosis or diuresis. Caution is advised; monitor infant for signs of acidosis or dehydration.
It is not known whether dichlorphenamide is excreted in human breast milk. The M/P ratio is unknown. Due to the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug.
Dose adjustments may be necessary due to increased renal clearance and volume of distribution in pregnancy. Monitor therapeutic effect and adverse reactions; consider starting at lower doses and titrating based on response. No standardized guidelines exist; individualize therapy.
No specific dose adjustments for pregnancy are established. However, due to pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance), careful monitoring of drug effect and tolerability is recommended. Dose may need individualized titration.
Acetazolamide is a carbonic anhydrase inhibitor used for altitude sickness prophylaxis, glaucoma, and as a diuretic. Monitor for metabolic acidosis, especially in elderly or renal impairment. Can cause hypokalemia; check serum potassium. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. May cause paresthesias, especially in hands and feet, which are harmless but can be distressing.
Dichlorphenamide is a carbonic anhydrase inhibitor used for primary open-angle glaucoma and familial periodic paralysis. Monitor serum potassium and perform baseline/periodic blood counts due to risk of hypokalemia and bone marrow suppression. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. Can cause metabolic acidosis; use cautiously in patients with respiratory acidosis or COPD. Dose adjustment required in renal impairment. May increase urate levels; avoid in gout unless urate-lowering therapy is used.
Take with food to reduce gastrointestinal upset.,May cause tingling in fingers, toes, or face; this is usually temporary and not harmful.,Drink plenty of fluids unless otherwise instructed to prevent kidney stones.,Avoid alcohol as it may increase side effects like dizziness.,Do not drive or operate machinery until you know how this medication affects you, as it may cause drowsiness or blurred vision.,Report any signs of unusual bleeding, bruising, or signs of infection to your healthcare provider.,Take exactly as prescribed; do not stop suddenly without consulting your doctor.,If used for altitude sickness, start 24-48 hours before ascent and continue for 48 hours at high altitude.
Take exactly as prescribed; do not skip doses to prevent glaucoma progression.,Report any signs of bleeding, bruising, fever, or sore throat immediately.,May cause drowsiness; avoid driving or operating heavy machinery until effects known.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol and aspirin-containing products to reduce risk of metabolic acidosis.,Drink plenty of fluids to prevent kidney stones; maintain adequate hydration.,Notify doctor if you have liver disease, kidney stones, or breathing problems.,This may increase blood sugar; monitor if diabetic.,Taste disturbances or altered sense of taste may occur and are usually reversible.
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAZOLAMIDE SODIUM vs DICHLORPHENAMIDE, answered by our medical review team.
ACETAZOLAMIDE SODIUM is a Carbonic Anhydrase Inhibitor that works by Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.. DICHLORPHENAMIDE is a Carbonic Anhydrase Inhibitor that works by Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAZOLAMIDE SODIUM and DICHLORPHENAMIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAZOLAMIDE SODIUM is: Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.. The standard adult dose of DICHLORPHENAMIDE is: 25-50 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAZOLAMIDE SODIUM and DICHLORPHENAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAZOLAMIDE SODIUM is classified as Category C. Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human d. DICHLORPHENAMIDE is classified as Category C. Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.